{
    "clinical_study": {
        "@rank": "30031", 
        "arm_group": [
            {
                "arm_group_label": "Levonorgestrel releasing intrauterine device, contraception", 
                "arm_group_type": "Experimental", 
                "description": "LNG-IUS - Mirena \u00ae,20\u03bcgr, once intrauterine insertion per 5 year, 1 year"
            }, 
            {
                "arm_group_label": "YASMIN\u00ae (Drospirenone/Ethinyl Estradiol), contraception", 
                "arm_group_type": "Experimental", 
                "description": "oral, once a day, 1 year"
            }, 
            {
                "arm_group_label": "Copper T 380 A , contraception", 
                "arm_group_type": "Experimental", 
                "description": "intrauterine device, once per 10 year, 1 year period"
            }
        ], 
        "brief_summary": {
            "textblock": "Oral combined contraceptives(OC) have both progesterone and estrogen inside.\n      Levonorgestrel-releasing intrauterine device(LNG_IUS) has only progestagen.\n\n      Copper IUD  does not have any hormonal molecule inside.\n\n        -  Hypothesis is OC has more systemic beneficial or side effects than LNG_IUS or copper\n           IUD. LNG_IUS has more local effects than copper IUD.\n\n        -  Study reflects the beneficial or side effects of estrogen+progestagen pills and only\n           progestogen inside device."
        }, 
        "brief_title": "Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality", 
        "condition": "Contraceptive Methods Comparison", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women who desire contraception\n\n        Exclusion Criteria:\n\n          -  Women with large fibroids,abnormal uterine bleeding including heavy menstrual\n             bleeding or using any contraceptive pills during the previous 3 months were excluded\n             from the study. Other exclusion criteria were pelvic inflammatory disease, pregnancy,\n             genital tumor or thromboembolic disease."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805817", 
            "org_study_id": "cuzuncakmak1907"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Levonorgestrel releasing intrauterine device, contraception", 
                    "YASMIN\u00ae (Drospirenone/Ethinyl Estradiol), contraception", 
                    "Copper T 380 A , contraception"
                ], 
                "description": "oral contraceptive pills", 
                "intervention_name": "YASMIN\u00ae (Drospirenone/Ethinyl Estradiol)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Levonorgestrel releasing intrauterine device, contraception", 
                    "YASMIN\u00ae (Drospirenone/Ethinyl Estradiol), contraception", 
                    "Copper T 380 A , contraception"
                ], 
                "description": "intrauterine device for contraception", 
                "intervention_name": "The Copper-T is an intrauterine device (IUD)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Levonorgestrel releasing intrauterine device, contraception", 
                    "YASMIN\u00ae (Drospirenone/Ethinyl Estradiol), contraception", 
                    "Copper T 380 A , contraception"
                ], 
                "description": "intrauterine device", 
                "intervention_name": "levonorgestrel-releasing system", 
                "intervention_type": "Device", 
                "other_name": "Miirena"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Levonorgestrel", 
                "Contraceptives, Oral", 
                "Copper", 
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol", 
                "Drospirenone", 
                "Drospirenone and ethinyl estradiol combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "lipid profile", 
            "bleeding scores", 
            "menstrual pattern", 
            "beneficial", 
            "side effects", 
            "changes in a year period"
        ], 
        "lastchanged_date": "March 6, 2013", 
        "link": {
            "description": "database for medical publication", 
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/?term=lng+ius+combined+oral+contraceptives"
        }, 
        "location": {
            "contact": {
                "email": "cuzuncakmak@gmail.com", 
                "last_name": "Cihangir Uzun\u00e7akmak, M.D.", 
                "phone": "0090 505 4505808"
            }, 
            "facility": {
                "address": {
                    "city": "Istanbul", 
                    "country": "Turkey", 
                    "zip": "34098"
                }, 
                "name": "Istanbul Training and Research Hospital"
            }, 
            "investigator": {
                "last_name": "Cihangir Uzuncakmak, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality", 
        "other_outcome": {
            "description": "60 lng-ius users, 60 Copper iud users and 60 combined oral contraceptive users menstrual pattern will be recorded and menstrual bleeding scores will be  measured by pictorial blood scoring system and it will be compared with each other at 3-6-12 months follow up.", 
            "measure": "menstrual pattern and bleeding scores(composite measurement)", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline pictorial blood scoring system scores at 3 months, Baseline to 6 months, Baseline to 12 months will be assessed"
        }, 
        "overall_contact": {
            "email": "cuzuncakmak@gmail.com", 
            "last_name": "Cihangir Uzun\u00e7akmak, M.D.", 
            "phone": "0090 505 4505808"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "TURKEY :\u0130stanbul Training and Research Hospital Obstetrics and Gynecology Admiministration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "60 lng-ius users, 60 Copper iud users and 60 combined oral contraceptive users will compared with total lipoprotein, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), lipoprotein(a) (Lp(a)), intermediate-density lipoprotein (IDL ), HDL subclasses , LDL subclasses , VLDL subclasses ,values at 3-6-12 months follow up.", 
            "measure": "Lipid profile (HDL,VLDL,IDL,LDL,Lp(a),VLDL)Lng-ius users, Copper-iud users and combined oral contraceptive users (composite measurement)", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline HDL,Very-low-density lipoprotein (VLDL),IDL,Low-density lipoprotein (LDL),Lp(a),VLDL concentrations at 3 months; Baseline to 6 months, Baseline to 12 months of outcome will have assessed"
        }, 
        "reference": [
            {
                "PMID": "21570557", 
                "citation": "Haliloglu B, Celik A, Ilter E, Bozkurt S, Ozekici U. Comparison of uterine artery blood flow with levonorgestrel intrauterine system and copper intrauterine device. Contraception. 2011 Jun;83(6):578-81. doi: 10.1016/j.contraception.2010.09.001. Epub 2010 Oct 18."
            }, 
            {
                "PMID": "21092958", 
                "citation": "Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011 Feb;112(2):126-30. doi: 10.1016/j.ijgo.2010.08.009. Epub 2010 Nov 19."
            }, 
            {
                "PMID": "22018120", 
                "citation": "Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception. 2011 Nov;84(5):465-77. doi: 10.1016/j.contraception.2011.04.002. Epub 2011 Jun 8. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805817"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istanbul Training and Research Hospital", 
            "investigator_full_name": "Cihangir Uzun\u00e7akmak", 
            "investigator_title": "Medical Doctor, OB/GYN", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "60 lng-ius users, 60 Copper iud users and 60 combined oral contraceptive users will compared with activated partial thromboplastin time (aPTT), prothrombin time, international normalized ratio(INR), D-dimer,factor VIII, fibrinogen,  platelet counts values with each other at 3-6-12 months follow up.", 
            "measure": "coagulation parameters(composite measurement)", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline aPTT, prothrombin time, INR, D-dimer,factor VIII, fibrinogen,  platelet counts values at 3 months; Baseline to 6 months, Baseline to 12 months of outcome will have assessed"
        }, 
        "source": "Istanbul Training and Research Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istanbul Training and Research Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}